Lauren Silvernail
Director/Board Member chez NICOX SA
Fortune : 285 880 $ au 31/03/2024
Profil
Lauren P.
Silvernail is currently a Director at Nicox Ophthalmics, Inc., an Independent Director at Nicox SA, a Director at Harrow, Inc., and a Member of the Licensing Executives Society.
Previously, she served as an Independent Director at Harpoon Therapeutics, Inc. from 2022 to 2024.
She was also the Vice President-Business Development at Allergan, Inc. from 1995 to 2003.
Additionally, she held positions as a Group Product Manager at Bio-Rad Laboratories, Inc. and as a Principal at Varian Medical Systems, Inc. From 2003 to 2012, she served as the VP, Chief Financial & Accounting Officer at ISTA Pharmaceuticals, Inc. She was the Chief Financial & Business Officer at Revance Therapeutics, Inc. from 2013 to 2018, and the CFO & Executive VP-Corporate Development at Evolus, Inc. from 2018 to 2022.
Prior to that, she was a General Partner at Glenwood Ventures in 1994.
Ms. Silvernail obtained an undergraduate degree from the University of California, Berkeley and an MBA from UCLA Anderson School of Management.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
EVOLUS, INC.
0,03% | 21/04/2023 | 20 420 ( 0,03% ) | 285 880 $ | 31/03/2024 |
Postes actifs de Lauren Silvernail
Sociétés | Poste | Début |
---|---|---|
NICOX SA | Director/Board Member | 18/05/2017 |
HARROW, INC. | Director/Board Member | 29/01/2024 |
Licensing Executives Society | Corporate Officer/Principal | - |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Director/Board Member | 01/01/2017 |
Anciens postes connus de Lauren Silvernail
Sociétés | Poste | Fin |
---|---|---|
HARPOON THERAPEUTICS, INC. | Director/Board Member | 11/03/2024 |
EVOLUS, INC. | Director of Finance/CFO | 31/05/2022 |
REVANCE THERAPEUTICS, INC. | Director of Finance/CFO | 29/05/2018 |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Director of Finance/CFO | 01/01/2012 |
ALLERGAN, INC. | Corporate Officer/Principal | 01/03/2003 |
Formation de Lauren Silvernail
University of California, Berkeley | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 6 |
---|---|
BIO-RAD LABORATORIES, INC. | Health Technology |
REVANCE THERAPEUTICS, INC. | Health Technology |
EVOLUS, INC. | Health Technology |
NICOX SA | Health Technology |
HARROW, INC. | Health Technology |
HARPOON THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Allergan, Inc.
Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Varian Medical Systems, Inc.
Varian Medical Systems, Inc. Medical SpecialtiesHealth Technology Varian Medical Systems, Inc. engages in the manufacture of medical devices and software for treating cancer and other medical conditions. It operates through the Oncology Systems and Proton Solutions segments. The Oncology Systems segment designs, manufactures, sells, and services hardware and software products for treating cancer with conventional radiation therapy, and advanced treatments. The Proton Solutions segment delivers proton therapy, a form of external beam radiotherapy using proton beams for the treatment of cancer. The company was founded by William Hansen, Edward Ginzton, Russell Varian, and Sigurd Varian in 1948 and is headquartered in Palo Alto, CA. | Health Technology |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Nicox Ophthalmics, Inc. develops ocular diseases treatment products. It offers extensive pipeline such as a number of clinical and pre-clinical programs that principally target ocular allergy, ocular inflammation, and blepharitis. The company was founded by Thomas Cavanagh on December 21, 2007 and is headquartered in Fort Worth, TX. | Health Technology |
Licensing Executives Society | |
Glenwood Ventures
Glenwood Ventures Investment ManagersFinance Glenwood Ventures is a commercial real estate investment firm that specializes in acquiring and developing various types of real estate assets, including industrial, office, life science, residential, and mixed-use properties. Glenwood Ventures was founded in 1900 and is based in Menlo Park, CA. The private company's team members have extensive experience in maximizing real estate value by identifying opportunities and operating assets for their clients and partners. | Finance |